Leqvio Market Report 2026

Leqvio Market Overview

• The Leqvio market growth in the historic period has been driven by increasing prevalence of hyperlipidemia, advancements in rna interference technology • Market expansion is supported by increasing adoption of novel rna therapeutics, rising focus on cardiovascular risk reduction • Growth Driver: Growing Geriatric Population Drives The Leqvio Market Expansion • Market Trend: Advancements In Long-Acting Injectable Therapies For High Cholesterol And Cardiovascular Risk Management • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Leqvio Market?

Leqvio is an siRNA-based therapy that reduces low-density lipoprotein (LDL) cholesterol by silencing the mRNA responsible for PCSK9 production in the liver. It improves the liver's ability to clear LDL-C from the bloodstream, lowering the risk of heart attacks, strokes, and other cardiovascular events in high-risk patients. The main types of leqvio formulation are injectable formulation (subcutaneous) and pre-filled syringes or auto-injectors. Leqvio's subcutaneous injectable formulation is administered in a healthcare setting, delivering a controlled, long-term dosage typically every six months after an initial dose. It is applicable for various indications, including treatment of hyperlipidemia, management of atherosclerotic cardiovascular disease (ASCVD), and treatment of familial hypercholesterolemia for several patient demographics, such as adult patients, geriatric patients, and patients with comorbid conditions. It is distributed by various distribution channels, including direct sales, wholesalers and distributors, retail pharmacies, and online pharmacies, and used by several end users, such as hospitals, cardiovascular clinics, specialty pharmacies, and home healthcare providers.

What Is The Leqvio Market Growth Forecast?

The growth in the forecast period can be attributed to increasing adoption of novel rna therapeutics, rising focus on cardiovascular risk reduction, expansion of long-interval dosing therapies, growing investments in cardiometabolic research, increasing demand for durable lipid-lowering solutions. Major trends in the forecast period include increasing adoption of sirna-based lipid-lowering therapies, rising demand for long-acting cardiovascular treatments, growing focus on preventive cardiology solutions, expansion of advanced rna manufacturing technologies, enhanced emphasis on patient adherence optimization.

Global Leqvio Market Segmentation

1) By Formulation: Injectable Formulation (Subcutaneous), Pre-Filled Syringes Or Auto-Injectors 2) By Indication: Treatment Of Hyperlipidemia, Management Of Atherosclerotic Cardiovascular Disease (ASCVD), Treatment Of Familial Hypercholesterolemia 3) By Patient Demographics: Adult Patients, Geriatric Patients, Patients with Comorbid Conditions 4) By Distribution Channel: Direct Sales, Wholesalers and Distributors, Retail Pharmacies, Online Pharmacies 5) By End-User: Hospitals, Cardiovascular Clinics, Specialty Pharmacies, Home Healthcare Providers

What Is The Driver Of The Leqvio Market?

The growing geriatric population is expected to boost the growth of the leqvio demand going forward. The geriatric population consists of individuals, usually aged 65 and above. Advancements in healthcare and medical technology have significantly boosted life expectancy, contributing to the growth of the geriatric population. Leqvio lowers LDL cholesterol, easing medication management for older adults. Its long-lasting effect reduces cardiovascular risks, enhancing health outcomes in the geriatric population. For instance, in January 2024, according to the Population Reference Bureau, a Kenya-based nonprofit organization, the population of Americans aged 65 and older is expected to grow from 58 million in 2022 to 82 million by 2050, a 47% increase. This age group's share of the overall population is also projected to rise from 17% to 23% during the same period. Therefore, the growing geriatric population is driving the growth of the leqvio industry.

Key Players In The Global Leqvio Market

Major companies operating in the leqvio market are Novartis AG

Global Leqvio Market Trends and Insights

Major companies are operating in the leqvio market, focusing on developing advanced injectable prescription medicine such as Label Expansion to enhance therapeutic accessibility and early intervention. Label Expansion refers to the regulatory approval granted by authorities, such as the FDA, that allows an already authorized drug to be used for additional indications, patient groups, or clinical settings beyond its original approved use. For instance, in July 2023, Novartis AG, a Switzerland-based pharmaceutical company, received US Food and Drug Administration (FDA) approval for a label update for Leqvio (inclisiran), allowing its use at an earlier stage for patients with elevated LDL-C and an increased risk of heart disease, in addition to diet and statin therapy. With two doses per year after two initial doses, it provides up to a 52% LDL-C reduction and is proven effective for patients unable to reach their LDL-C target despite statin therapy. The label update highlights robust safety and efficacy data reinforced by the VictORION clinical trial program.

What Are Latest Mergers And Acquisitions In The Leqvio Market?

In November 2019, Novartis AG, a Switzerland-based pharmaceutical company, acquired The Medicines Company for US$ 9.7 billion. With this acquisition, Novartis gained global rights to inclisiran (later branded Leqvio) and significantly strengthened its cardiovascular‑lipid lowering franchise. The Medicines Company was a US-based biopharma firm focused on siRNA-based cholesterol-lowering therapies under license from Alnylam.

Regional Insights

North America was the largest region in the leqvio market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Leqvio Market?

The leqvio market consists of sales of multi-dose vials and ready-to-use liquid vials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Leqvio Market Report 2026?

The leqvio market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the leqvio industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.